Cardiac tumors secondary prevention

Jump to navigation Jump to search

Cardiac tumors Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiac Tumors from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac tumors secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac tumors secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac tumors secondary prevention

CDC on Cardiac tumors secondary prevention

Cardiac tumors secondary prevention in the news

Blogs on Cardiac tumors secondary prevention

Directions to Hospitals Treating Cardiac tumors

Risk calculators and risk factors for Cardiac tumors secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Template:Dj

Overview

The secondary prevention can be used in the treatment of cardiac tumors in children to prevent the adverse effects of Anthracyclines. Anthracyclines are commonly used in the treatment of cardiac malignancy in children.

Secondary Prevention

Definition: Secondary prevention focuses on early illness identification and targets persons who appear healthy but have subclinical disease types. The subclinical disease is characterized by pathologic alterations, but lacks overt manifestations that can be diagnosed during a doctor's visit.

Echocardiograph can be used for screening in patients with Tuberous sclerosis and other genetic syndromes and help in secondary prevention.

  • The concept of secondary prevention is effective in the chemotherapeutic treatment of cardiac tumors in children.
    • Most pharmaceutical approaches for long-term tumor survivors exposed to cardiotoxic medications have been adopted from investigations of adults.
    • The lifestyle changes and reduction of cardiac risk factors after the development of cardiac failure due to chemo. constitute secondary prevention.
    • To avoid the development of silent LVSD to clinical disease, these measures include proactive screening and administration of angiotensin-converting enzyme (ACE) inhibitors and Beta-blockers.[1]

References

  1. Chow EJ, Leger KJ, Bhatt NS, Mulrooney DA, Ross CJ, Aggarwal S; et al. (2019). "Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment". Cardiovasc Res. 115 (5): 922–934. doi:10.1093/cvr/cvz031. PMC 6452306. PMID 30768157.